Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)

NCT04629105 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

ARDS, Human
Covid19

Interventions

BIOLOGICAL: Longeveron Mesenchymal Stem Cells (LMSCs)
OTHER: Placebo

Sponsor

Longeveron Inc.